SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

Inovio Says Preclinical Data Suggest Potential of COVID-19 Vaccine Candidate Against Different Viral Variants

05/12/2021 04:41

08:35 AM EDT, 05/12/2021 (MT Newswires) -- Inovio Pharmaceuticals (INO) said Wednesday its COVID-19 vaccine candidate may have potential to induce immune responses against different variants of the SARS-CoV-2 virus, based on data from its preclinical study.

In the study, the vaccine induced potent neutralizing antibodies and T-cell responses against the original strain, as well as the UK, South African, and Brazilian variants of the virus.

The company is now planning to conduct phase 1/2 clinical trials this year, according to the statement.

Shares in the drug maker were up more than 4% in recent premarket activity Wednesday.

Price: 6.77, Change: +0.28, Percent Change: +4.31